Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZIGIR
- Development stage
- Preclinical
- Lead developer
- UT Southwestern Medical Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ZIGIR (zinc granule indicator) is a cell-permeable, fluorescent zinc-chelating dye developed by researchers at the University of Texas Southwestern Medical Center. It is designed to selectively label zinc-rich secretory granules, particularly insulin-containing granules in pancreatic beta cells, with high specificity and sensitivity. ZIGIR exhibits a greater than 100-fold fluorescence enhancement upon binding to zinc (Zn2+) and is refractory to physiological pH fluctuations, making it highly suitable for imaging acidic compartments like secretory granules. It is used as a diagnostic and research imaging agent to visualize islet cells, monitor insulin granule dynamics, and assess islet revascularization in vivo after transplantation.
- Other names
- fluorescent zinc granule indicatorZI-GIRzinc granule indicator
Beyond the preview
Go deeper on ZIGIR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZIGIR.